Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens

Current Medical Research and Opinion

Volumn 20, Issue 4, 2004, Pages 555-563

  Dunbar, Lala M ^a   Khashab, Mohammed M ^b   Kahn, James B ^b   Zadeikis, Neringa ^b   Xiang, Jim X ^b   Tennenberg, Alan M ^b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Atypical pathogens; Community acquired pneumonia; Levofloxacin

Indexed keywords

LEVOFLOXACIN;

ADULT; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNITED STATES; VIRUS PNEUMONIA;

ADULT; ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEGIONNAIRES' DISEASE; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA;

EID: 1942534571     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003304     Document Type: Conference Paper

References (32)

1. Schlick W. The problems of treating atypical pneumonia. J Antimicrob Chemother 1993;31:C111-C120
2. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000;31:S35-S39
3. File Jr. TM. The epidemiology of respiratory tract infections. Semin Respir Infect 2000;15:184-94
4. Marston BJ, Plouffe JF, File Jr. TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997;157:1709-18
5. Bochud P-Y, Moser F, Erard P, et al. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore) 2001;80:75-87
6. Falguera M, Sacristan O, Nogues A, et al. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001;161:1866-72
7. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99
8. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54
9. Mandell LA, Bartlett JG, Dowell SF, File Jr. TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33
10. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infection 2002;8:214-21
11. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003;47:2450-7
12. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia -implications for practice guidelines. J Am Med Assoc 1998;279:1452-7
13. File Jr. TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-72
14. Fogarty CM, Sullivan JG, Chattman MS, Williams RR, Kojak C, Rubin A. Once a day levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults. Infect Dis Clin Pract 1998;7:400-7
15. Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin vs ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin/clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2003;38(suppl 1):S16-S23
16. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60
17. Tennenberg AM, Khashab MM, Xiang JX, Wiesinger BA, Zadeikis N, Kahn JB. 750 mg, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Presented at the 99th International Coference of the American Thoracic Society, Seattle, WA, 2003
18. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community- acquired pneumonia. New Engl J Med 1997;336:243-50
19. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Morb Mortal Wkly Rep 1997;46:1-55
20. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503
21. Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993;17(suppl 1):S79-S82
22. Altman DG. Practical statistics for medical research. Chapman and Hall, 1991
23. Akpunonu B, Michaelis J, Tennenberg A, et al. Multicenter, postmarketing assessment of levofloxacin in the treatment of adults with community-acquired pneumonia. Clin Infect Dis 2003;38(suppl 1):S5-S15
24. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996;101:508-15
25. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis 2003;36:963-70
26. Schonwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection 1999;27:198-202
27. Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 1998;10:64-8
28. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001;45:1037-42
29. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001;119:1114-22
30. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002;44:43-9
31. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7
32. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-85